Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer

Metastatic Triple-Negative Breast Cancer Clinical Trial

— ToPCourT  

Official title:

ToPCourT: A Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (TNBC)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06027268
• Other study ID #: IRB00095334
• Secondary ID: LCI-BRE-MTN-TPGC
• Status: Recruiting
• Phase: Phase 2
• Start date: January 10, 2024
• Est. completion date: March 2027

Study information

• Verified date: May 2024
• Source: Wake Forest University Health Sciences
• Contact: Leah Wilson
• Phone: (980) 442-2333
• Email: leah.j.wilson[@]atriumhealth.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this phase II study is to test the combination of trilaciclib, pembrolizumab, gemcitabine, and carboplatin in locally advanced unresectable or metastatic triple-negative breast cancer.

The main questions it aims to answer are:

• to evaluate the anti-cancer efficacy (assess how well it works)

• to evaluate the safety and tolerability (how well the body can handle the treatment) of this combination of anti-cancer therapy

Description:

This is an open label, single-arm, phase II trial designed to evaluate the efficacy of trilaciclib, pembrolizumab, gemcitabine and carboplatin in participants with locally advanced unresectable or metastatic triple-negative breast cancer. Pembrolizumab will be given for a maximum of 2 years. Eligible participants will receive the study treatment until disease progression, unacceptable toxicity, or withdrawal for any reason. A tumor biopsy will be collected from participants in which it can be safely obtained before the first dose of treatment, prior to Cycle 3 Day 1, and at the time of disease progression (optional). Blood specimens for correlative studies will be collected pre-treatment Cycle 1 Day 1, prior to treatment Cycle 2 Day 1, prior to treatment Cycle 3 Day 1, 3 months after the start of study treatment, and 6 months after the start of study treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 36
• Est. completion date: March 2027
• Est. primary completion date: September 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Written informed consent and HIPAA authorization for release of personal health information signed by the patient

2. Male or female with locally advanced unresectable or metastatic TNBC

3. Age = 18 years at the time of consent

4. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1 evaluated within 28 days prior to day 1 of study treatment

5. Histological or cytological confirmation of estrogen negative and progesterone negative tumor, defined as < 10% staining on immunohistochemistry (IHC) and human epidermal growth factor receptor type 2 (HER2)-negative, defined as IHC 0 or 1+ or fluorescence in-situ hybridization (FISH) HER2: chromosome enumeration probe 17 (CEP) ratio <2.0 with an average copy number of <4 signals/nucleus per 2018 American Society of Clinical Oncology and the College of American Pathologists (ASCO CAP) criteria. Patients may be enrolled regardless of their PD-L1 (programmed death ligand-1) status.

6. Measurable disease according to response evaluation criteria in solid tumors

7. Demonstrate adequate organ function

8. Female patients: All females of childbearing potential must have a negative serum ß-human chorionic gonadotropin (hCG) test result at Screening and negative serum or urine pregnancy test results within 72 hours prior to day 1 of study treatment.

9. Subject agrees to use contraception

10. As determined by the enrolling physician, the ability of the subject to understand and comply with study procedures for the entire length of the study

11. Tumor tissue: Willing to provide tumor tissue for research purposes

12. Subject has a life expectancy of = 12 weeks

Exclusion Criteria:

1. More than 3 prior lines of chemotherapy for locally advanced unresectable or triple-negative metastatic disease

2. Prior therapy with the concurrent combination of gemcitabine and carboplatin in the metastatic setting

3. Active, symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis or CNS metastases that are progressing on screening magnetic resonance imaging (MRI) brain.

4. Prior systemic anti-cancer therapy within 3 weeks, prior stereotactic radiotherapy within 1 week, and radiation within 2 weeks of day 1 of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation to non-CNS disease.

5. Major surgery, defined by the investigator's discretion, within 3 weeks of day 1 of study treatment

6. Not recovered from all reversible acute toxic effects of prior therapy, including non-hematologic toxicities related to prior systemic therapy to = Grade 1. Participants with less than Grade 2 neuropathy or alopecia of any grade are an exception

7. Active infection requiring systemic therapy

8. Pregnant or breastfeeding

9. Participants previously diagnosed with an additional malignancy must be disease-free for at least five years prior to enrollment. Exceptions include basal cell or squamous cell skin cancer and in situ cervical or bladder cancer.

10. Treatment with any investigational drug within 30 days or at least 5 half-lives, whichever is longer, prior to day 1 of study treatment

11. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, uncontrolled symptomatic congestive heart failure (Class III or IV as defined by the New York Heart Association (NYHA) functional classification system), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations/substance abuse that would limit compliance with study requirements as determined by the investigator

12. Known history of stroke or cerebrovascular event within 6 months prior to the day 1 of study treatment

13. Known hypersensitivity to carboplatin or other platinum-containing compounds, gemcitabine, mannitol, or pembrolizumab

14. History of non-infectious interstitial lung disease (ILD)/pneumonitis that required steroids or current ILD/ pneumonitis.

15. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs) prior to day 1 of study treatment. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed

16. Prior hematopoietic stem cell or bone marrow transplant or allogenic tissue/solid organ transplant

17. Has a known history of Human Immunodeficiency Virus (HIV) or known acquired immunodeficiency syndrome (AIDS)

18. Has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive).

19. Has known active hepatitis C (e.g., hepatitis C virus (HCV) ribonucleic acid (RNA) [qualitative] is detected).

20. Receipt of a live, attenuated vaccine within 30 days prior to day 1 of study treatment or anticipation that such a live, attenuated vaccine will be required during the study treatment period. Administration of killed vaccines is allowed. Exception: Monkeypox vaccine may be given if there are at least 3 days between the vaccine and initiation of study treatment.

Related Conditions & MeSH terms

• Breast Neoplasms
• Metastatic Triple-Negative Breast Cancer
• Triple Negative Breast Neoplasms

Intervention

Drug:
• Trilaciclib
IV infusion Day 1 and Day 8 every 21 days, at dose of 240 mg/m2
• Pembrolizumab
IV infusion Day 1 every 21 days, at dose of 200 mg
• Gemcitabine
IV infusion Day 1 and Day 8 every 21 days, at dose 1000 mg/m2
• Carboplatin
IV infusion Day 1 and Day 8 every 21 days, at dose area under curve (AUC) 2 (maximum of 300 mg)

Locations

Country	Name	City	State
United States	Levine Cancer Institute	Charlotte	North Carolina

Sponsors (3)

Lead Sponsor	Collaborator
Wake Forest University Health Sciences	G1 Therapeutics, Inc., Merck Sharp & Dohme LLC

Country where clinical trial is conducted

United States, 

References & Publications (3)

Tan AR, O'Shaughnessy J, Cao S, Ahn S, Yi JS. Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer. Breast Cancer Res Treat. 2023 Sep;201(2):307-316. doi: 10.1007/s10549-023-07009-8. Epub 2023 Jul 7. — View Citation

Tan AR, Wright GS, Thummala AR, Danso MA, Popovic L, Pluard TJ, Han HS, Vojnovic Z, Vasev N, Ma L, Richards DA, Wilks ST, Milenkovic D, Xiao J, Sorrentino J, Horton J, O'Shaughnessy J. Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study. Clin Cancer Res. 2022 Feb 15;28(4):629-636. doi: 10.1158/1078-0432.CCR-21-2272. — View Citation

Tan AR, Wright GS, Thummala AR, Danso MA, Popovic L, Pluard TJ, Han HS, Vojnovic Z, Vasev N, Ma L, Richards DA, Wilks ST, Milenkovic D, Yang Z, Antal JM, Morris SR, O'Shaughnessy J. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial. Lancet Oncol. 2019 Nov;20(11):1587-1601. doi: 10.1016/S1470-2045(19)30616-3. Epub 2019 Sep 28. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Adverse Events	Trilaciclib, pembrolizumab, gemcitabine, and carboplatin treatment administration AEs while on study therapy	30 days (initiation of protocol directed therapy until 30 days after last dose, or removal from study while on treatment)
Other	Serious Adverse Events	Trilaciclib, pembrolizumab, gemcitabine, and carboplatin treatment administration SAEs while on study therapy	30 days (initiation of protocol directed therapy until 30 days after last dose, or removal from study while on treatment)
Other	Adverse Event Related Dose Delays	Trilaciclib, pembrolizumab, gemcitabine, and carboplatin treatment administration AE-related dose delays while on study therapy	30 days (initiation of protocol directed therapy until 30 days after last dose, or removal from study while on treatment)
Other	Dose Reductions	Trilaciclib, pembrolizumab, gemcitabine, and carboplatin treatment administration dose reductions while on study therapy	30 days (initiation of protocol directed therapy until 30 days after last dose, or removal from study while on treatment)
Other	Treatment Discontinuation	Trilaciclib, pembrolizumab, gemcitabine, and carboplatin treatment administration treatment discontinuation while on study therapy	30 days (initiation of protocol directed therapy until 30 days after last dose, or removal from study while on treatment)
Other	Deaths	Trilaciclib, pembrolizumab, gemcitabine, and carboplatin treatment administration deaths while on study therapy	30 days (initiation of protocol directed therapy until 30 days after last dose, or removal from study while on treatment)
Primary	Objective Response	Objective according to RECIST v1.1 criteria	6 months (initiation of protocol directed therapy until either a partial response is achieved or treatment discontinuation)
Secondary	Progression-free survival	Time to disease progression per RECIST v1.1 criteria or death	1 year (initiation of protocol directed therapy until documented disease progression, death, or end of follow-up period)
Secondary	Duration of response	Duration of response will be calculated only for subjects who achieve an objective response according to RECIST v1.1 criteria (a CR or PR). Disease progression will be objectively determined as per RECIST 1.1 criteria or progression can be subjective as determined by the Investigator.	1 year (time from first disease assessment that shows a PR or complete response (CR) until documented disease progression, death, or end of follow-up period)
Secondary	Overall survival	Time to date of death due to any cause while on study	1 year (initiation of protocol directed therapy until documented death, or end of follow-up period])